DR
Therapeutic Areas
Spruce Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tralesinidase Alfa (TA-ERT) | Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B) | Phase 3 |
Leadership Team at Spruce Biosciences
JS
Javier Szwarcberg
Chief Executive Officer
SG
Samir Gharib
President and Chief Financial Officer
KW
Kirk Ways
Chief Medical Officer
SS
Saba Sile
Vice President, Clinical Development
MG
Michael Grey
Executive Chairman
PB
Percival Barretto-Ko
Independent Director
CV
Camilla V. Simpson
Independent Director
DS
Dan Spiegelman
Independent Director
KW
Keli Walbert
Independent Director